Alkermes Plc  

(Public, NASDAQ:ALKS)   Watch this stock  
Find more results for alks
-1.14 (-3.42%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 31.14 - 33.36
52 week 29.67 - 80.71
Open 33.14
Vol / Avg. 3.07M/2.03M
Mkt cap 4.66B
P/E     -
Div/yield     -
EPS -0.85
Shares 150.06M
Beta 1.90
Inst. own 99%
Feb 11, 2016
Alkermes Plc at Leerink Partners Global Healthcare Conference - 12:00PM EST - Add to calendar
Feb 9, 2016
Alkermes Plc at Biotechnology Industry Organization (BIO) CEO & Investor Conference - 3:00PM EST - Add to calendar
Jan 12, 2016
Alkermes Plc at JPMorgan Healthcare Conference - Q&A Session
Jan 12, 2016
Alkermes Plc at JPMorgan Healthcare Conference
Nov 18, 2015
Alkermes Plc at Jefferies Autumn Global Healthcare Conference - Webcast
Nov 10, 2015
Alkermes Plc at Credit Suisse Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -53.07% -4.86%
Operating margin -50.71% -14.08%
EBITD margin - 1.77%
Return on average assets -17.12% -1.72%
Return on average equity -23.50% -2.44%
Employees 1,300 -
CDP Score - -


Connaught House 1 Burlington Road, Dublin 4
DUBLIN, 00000
+353-1-7728000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders, such as addiction, schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil, ALKS 5461, ALKS 3831, ALKS 8700 and RDB 1419. The Company's main marketed products include RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, AMPYRA/FAMPYRA, BYDUREON and VIVITROL.

Officers and directors

Richard F. Pops Chairman, President, and CEO
James M. (Jim) Frates SVP, CFO, and Treasurer
Gordon G. Pugh SVP, COO, and Chief Risk Officer
Richard F. Pops Chairman of the Board, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Shane M. Cooke President
Age: 52
Bio & Compensation  - Reuters
James M. Frates Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gordon G. Pugh Chief Operating Officer, Senior Vice President, Chief Risk Officer
Age: 57
Bio & Compensation  - Reuters
Elliot W. Ehrich M.D. Executive Vice President, Research and Development and Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Kathryn L. Biberstein Senior Vice President, Chief Legal Officer and Chief Compliance Office, Secretary
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Rebecca J. Peterson Senior Vice President - Corporate Communications
Age: 39
Bio & Compensation  - Reuters